Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Assets Average (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Assets Average for 11 consecutive years, with $166.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average rose 11.77% year-over-year to $166.7 million, compared with a TTM value of $166.7 million through Sep 2025, up 11.77%, and an annual FY2024 reading of $161.2 million, down 30.34% over the prior year.
  • Assets Average was $166.7 million for Q3 2025 at CytomX Therapeutics, up from $136.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $418.3 million in Q2 2021 and bottomed at $109.5 million in Q1 2025.
  • Average Assets Average over 5 years is $241.8 million, with a median of $221.9 million recorded in 2023.
  • Peak annual rise in Assets Average hit 11.77% in 2025, while the deepest fall reached 43.33% in 2025.
  • Year by year, Assets Average stood at $355.3 million in 2021, then crashed by 31.42% to $243.7 million in 2022, then fell by 13.22% to $211.5 million in 2023, then plummeted by 38.64% to $129.8 million in 2024, then grew by 28.44% to $166.7 million in 2025.
  • Business Quant data shows Assets Average for CTMX at $166.7 million in Q3 2025, $136.8 million in Q2 2025, and $109.5 million in Q1 2025.